Alvotech, a global biotech company, will announce Q4 and full year 2025 results on March 18, 2026 after US markets close.

On March 4, 2026, in Reykjavik, Iceland, the biotechnology company Alvotech (NASDAQ: ALVO) shared its plan to unveil the financial and operating outcomes for the fourth quarter and full year 2025 on March 18, 2026. The disclosure will happen post the U.S. markets' closure, showcasing the company's progress in developing and producing biosimilar treatments for global patients.